Jason Incorvati

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

E. Hamilton, Maila Dayane Capuchinho de Oliveira, Nicholas C. Turner et al. · Annals of Oncology · 2024 · 62 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.

Erika Hamilton, Mafalda Oliveira, Udai Banerji et al. · Journal of Clinical Oncology · 2020 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.

Mafalda Oliveira, Erika Hamilton, Jason Incorvati et al. · Journal of Clinical Oncology · 2022 · 42 citations

Medicine, Oncology, Pharmacology +15

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

Richard D. Baird, Mafalda Oliveira, Eva María Ciruelos Gil et al. · Cancer Research · 2021 · 32 citations

Medicine, Oncology, Pharmacology +15

Abstract P3-07-28: SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer

Nicholas C. Turner, Christos Vaklavas, Emiliano Calvo et al. · Cancer Research · 2023 · 14 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17